1
|
Liu Y, Tu Y, Xiao J, Shen Y, Zhou B, Yang Q, Yu L, Qi L, Chen J, Liu T, Wu D, Xu Y. Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy. Blood Cancer J 2024; 14:39. [PMID: 38448401 PMCID: PMC10917735 DOI: 10.1038/s41408-024-01020-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2023] [Revised: 02/15/2024] [Accepted: 02/21/2024] [Indexed: 03/08/2024] Open
Affiliation(s)
- Yujie Liu
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China
| | - Yuqing Tu
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China
| | - Jinyan Xiao
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China
| | - Yifan Shen
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China
| | - Biqi Zhou
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China
| | - Qiannan Yang
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China
| | - Lei Yu
- Shanghai Unicar Therapy Bio-Medicine Technology Co. Ltd, Shanghai, China
| | - Lijuan Qi
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China
| | - Jia Chen
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China
| | - Tianhui Liu
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China.
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China.
| | - Depei Wu
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China.
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China.
| | - Yang Xu
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China.
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China.
| |
Collapse
|
2
|
Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study. J Cancer Res Clin Oncol 2021; 148:1493-1500. [PMID: 34319443 DOI: 10.1007/s00432-021-03749-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2021] [Accepted: 07/26/2021] [Indexed: 02/05/2023]
Abstract
PURPOSE To investigate the impact of delayed adjuvant imatinib on GIST patients with high risk of recurrence. METHOD Adult GIST patients were retrospectively collected from our hospital between 2011 and 2018, and patients having high risk of recurrence were included for subsequent analyses. The primary endpoint was recurrence-free survival (RFS). RESULTS According to the interval between the radical surgery and the beginning of adjuvant imatinib, 222 patients were divided into three groups: group A (≤ 2 months, n = 41), group B (2-≤ 4 months, n = 113), and group C (4-≤ 6 months, n = 68). Univariate, multivariate, and survival analyses all showed that patients in group A had significantly more favorable RFS than those in group C but not group B, and patients taking adjuvant imatinib for over 12 months were also associated with longer RFS comparing to adjuvant imatinib of ≤ 12 months. When stratified by the duration of adjuvant imatinib, no significant differences were found in RFS among groups A, B, and C for adjuvant imatinib of ≤ 12 months. While for adjuvant imatinib of over 12 months, both groups A and B had significantly more favorable RFS than group C, and no significant difference in RFS was found between group A and B. CONCLUSION Delayed postoperative adjuvant imatinib for over 4 months in patients with high risk of recurrence of GIST may lead to worse RFS, and longer treatment with shorter delay has best results.
Collapse
|
3
|
Leighow SM, Liu C, Inam H, Zhao B, Pritchard JR. Multi-scale Predictions of Drug Resistance Epidemiology Identify Design Principles for Rational Drug Design. Cell Rep 2021; 30:3951-3963.e4. [PMID: 32209458 PMCID: PMC8000225 DOI: 10.1016/j.celrep.2020.02.108] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Revised: 09/09/2019] [Accepted: 01/27/2020] [Indexed: 01/08/2023] Open
Abstract
Rationally designing drugs that last longer in the face of biological evolution is a critical objective of drug discovery. However, this goal is thwarted by the diversity and stochasticity of evolutionary trajectories that drive uncertainty in the clinic. Although biophysical models can qualitatively predict whether a mutation causes resistance, they cannot quantitatively predict the relative abundance of resistance mutations in patient populations. We present stochastic, first-principle models that are parameterized on a large in vitro dataset and that accurately predict the epidemiological abundance of resistance mutations across multiple leukemia clinical trials. The ability to forecast resistance variants requires an understanding of their underlying mutation biases. Beyond leukemia, a meta-analysis across prostate cancer, breast cancer, and gastrointestinal stromal tumors suggests that resistance evolution in the adjuvant setting is influenced by mutational bias. Our analysis establishes a principle for rational drug design: when evolution favors the most probable mutant, so should drug design. Drug resistance is often addressed through next-generation drug design, but evolutionary diversity complicates these efforts. Here, Leighow et al. demonstrate that multi-scale models can quantitatively predict mutant frequency. We find that when heterogeneity is limited, analysis requires an understanding of substitution likelihood. We show that these models can inform evolutionarily optimized drug design.
Collapse
Affiliation(s)
- Scott M Leighow
- The Pennsylvania State University, Department of Biomedical Engineering, University Park, PA 16802, USA
| | - Chuan Liu
- The Pennsylvania State University, Department of Biomedical Engineering, University Park, PA 16802, USA; Department of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
| | - Haider Inam
- The Pennsylvania State University, Department of Biomedical Engineering, University Park, PA 16802, USA
| | - Boyang Zhao
- The Pennsylvania State University, Department of Biomedical Engineering, University Park, PA 16802, USA
| | - Justin R Pritchard
- The Pennsylvania State University, Department of Biomedical Engineering, University Park, PA 16802, USA; The Huck Institute for the Life Sciences, Center for Resistance Evolution, The Pennsylvania State University, University Park, PA 16802, USA.
| |
Collapse
|
4
|
Limsuwanachot N, Kongruang A, Rerkamnuaychoke B, Singdong R, Niparuck P, Jootar S, Siriboonpiputtana T. Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand. Asian Pac J Cancer Prev 2020; 21:2003-2012. [PMID: 32711426 PMCID: PMC7573403 DOI: 10.31557/apjcp.2020.21.7.2003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2020] [Indexed: 11/28/2022] Open
Abstract
Objective: The genetic hallmark of CML is known as the appearance of t(9;22)(q34.1;q11.2) (BCR-ABL1) which is present in more than 95% of cases. Here, we demonstrated practical laboratory tools for monitoring of BCR-ABL1 transcripts in chronic myeloid leukemia patients undergoing TK inhibitor therapy. Methods: Real time quantitative PCR and direct sequencing were performed for monitoring of BCR-ABL1 transcripts in 245 treated CML. Results: At month 3 after first time point of monitoring, we found that 89% (218/245), 2% (5/245), and 9% (22/245) of patients are determined as optimal, warning, and failure response, respectively. The responses to TKI were slightly decreased at months 6 as following 73% optimal (180/245), 18% warning (43/245), and 9% failure response (22/245). Additionally, responses to TKI were gradually decreased at month 12 after first time point of monitoring as following 65% optimal (160/245), 13% warning (31/245), and 22% failure (54/245). We could detect 20% (49/245) of patients positive for BCR-ABL1 TKD mutations. Interestingly, one third (17 of 49) of TKD mutated cases were positive for compound/polyclonal mutation patterns. While major molecular response were observed in the majority of patients without TKD mutation, resistant to TKI were detected in patients with T315I mutation (n = 9; % mean IS = 8.1510, % median IS = 9.7000), compound/polyclonal mutations with T315I (n = 9; % mean IS = 13.0779, % median IS = 5.404), and other TKD mutations (n = 14; % mean IS = 8.1416, % median IS = 1.060), respectively. Conlusion: These practical laboratory techniques provided a more comprehensive understanding of CML progression during drug therapy and could be of benefit in earlier prognosis.
Collapse
Affiliation(s)
- Nittaya Limsuwanachot
- Human Genetic Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Adcharee Kongruang
- Human Genetic Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Budsaba Rerkamnuaychoke
- Human Genetic Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Roongrudee Singdong
- Doctoral Program in Clinical Pathology, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Pimjai Niparuck
- Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Saengsuree Jootar
- Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Teerapong Siriboonpiputtana
- Human Genetic Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| |
Collapse
|
5
|
Zhou L, Shi H, Shi W, Yang L, Zhang Y, Xu M, Chen X, Zhu Y, Mu H, Wan X, Yang Z, Zeng Y, Liu H. Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy. Onco Targets Ther 2019; 12:10989-10995. [PMID: 31997880 PMCID: PMC6917542 DOI: 10.2147/ott.s232102] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Accepted: 12/02/2019] [Indexed: 01/01/2023] Open
Abstract
Despite the prominent effects of BCR-ABL tyrosine kinase inhibitors (TKI) therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML) and thus low incidence of blastic transformation, blast phase (BP)-CML remains a major therapeutic challenge in the TKI era. The "gatekeeper" mutation T315I in BCR-ABL1 kinase, which often coupled with a poor prognosis, is quite common and resistant to all TKIs except for ponatinib. The occurrence of T315I mutation in BP-CML makes the situation more complex. Anti-CD19 chimeric antigen receptor T cell (CAR-T) technology is a new immunotherapy which has significantly improved the efficacy of B cell hematologic malignances. Here we report a lymphoid BP-CML patient harboring T315I mutation who achieved complete molecular remission and returned to chronic phase by anti-CD19 CAR-T therapy. Our study provides a new therapeutic strategy for patients in BP-CML.
Collapse
Affiliation(s)
- Lu Zhou
- Hematology Department, Affiliated Hospital of Nantong University, Nantong, People's Republic of China
| | - Huiping Shi
- Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
| | - Wenyu Shi
- Hematology Department, Affiliated Hospital of Nantong University, Nantong, People's Republic of China
| | - Li Yang
- Hematology Department, Affiliated Hospital of Nantong University, Nantong, People's Republic of China
| | - Yaping Zhang
- Hematology Department, Affiliated Hospital of Nantong University, Nantong, People's Republic of China
| | - Mengqi Xu
- Hematology Department, Affiliated Hospital of Nantong University, Nantong, People's Republic of China
| | - Xiufang Chen
- Hematology Department, Affiliated Hospital of Nantong University, Nantong, People's Republic of China
| | - Yanv Zhu
- Hematology Department, Affiliated Hospital of Nantong University, Nantong, People's Republic of China
| | - Hui Mu
- Hematology Department, Affiliated Hospital of Nantong University, Nantong, People's Republic of China
| | - Xiaochun Wan
- Shenzhen Bin De Bio Tech Co. Lid, Shenzhen, People's Republic of China
| | - Zhonghua Yang
- Shenzhen Bin De Bio Tech Co. Lid, Shenzhen, People's Republic of China
| | - Ying Zeng
- Shenzhen Bin De Bio Tech Co. Lid, Shenzhen, People's Republic of China
| | - Hong Liu
- Hematology Department, Affiliated Hospital of Nantong University, Nantong, People's Republic of China
| |
Collapse
|
6
|
Yoo HL, Kim SH, Choi SY, Lee SE, Kim DW. Optimal Time Points for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis on the Basis of European LeukemiaNet Recommendations in Chronic Myeloid Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2019; 19:406-412.e1. [PMID: 30928650 DOI: 10.1016/j.clml.2019.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Revised: 02/09/2019] [Accepted: 02/11/2019] [Indexed: 11/16/2022]
Abstract
BACKGROUND In this study we aimed to evaluate appropriate time points for mutation analysis of chronic myeloid leukemia. PATIENTS AND METHODS In total, 961 blood samples obtained from 605 chronic-phase chronic myeloid leukemia patients treated with imatinib were subjected to Sanger sequencing to detect BCR-ABL1 mutations. Mutation frequencies at landmark time points (3, 6, and 12 months) were assessed with 16 landmark responses defined by European LeukemiaNet and 2 additional responses, including a complete hematologic response (CHR) at 3 months and a complete cytogenetic response (CCyR) at 12 months. RESULTS After 12 months of imatinib treatment of 605 patients, 28 (4.6%) patients harbored 33 mutations, including 23 (69.7%) highly resistant T315I and P-loop mutations. Sequencing data from 650 samples were compared with cytogenetic responses. The mutation frequencies in optimal, warning, and failure groups were 0.5% (2/430), 1.8% (2/110), and 19.1% (21/110), respectively. The molecular response was assessed using 956 samples, and the mutation frequencies were 0.7% (3/425), 3.4% (12/358), and 7.6% (14/173) for the optimal, warning, and failure groups, respectively. For the 2 additional responses, the mutation frequencies in patients with CHR at 3 months and with CCyR at 12 months were 0% (0/160) and 1.7% (4/242), respectively. Overall, mutations were frequently detected at 3-month cytogenetic failure (25.0%), 12-month cytogenetic failure (23.2%), and 6-month cytogenetic failure (10.5%) using response-mutation association analysis. CONCLUSION Irrespective of mutation frequency, failure of achievement of a cytogenetic response should be conducted with appropriate mutation analysis.
Collapse
Affiliation(s)
- Hea-Lyun Yoo
- Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea
| | - Soo-Hyun Kim
- Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea
| | - Soo-Young Choi
- Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea
| | - Sung-Eun Lee
- Department of Hematology, Seoul St Mary's Hematology Hospital, The Catholic University of Korea, Seoul, South Korea
| | - Dong-Wook Kim
- Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea; Department of Hematology, Seoul St Mary's Hematology Hospital, The Catholic University of Korea, Seoul, South Korea.
| |
Collapse
|
7
|
Long-term outcome of GIST patients treated with delayed imatinib therapy. Eur J Cancer 2017; 78:118-121. [DOI: 10.1016/j.ejca.2017.03.024] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Revised: 02/03/2017] [Accepted: 03/23/2017] [Indexed: 11/19/2022]
|
8
|
Kurtovic-Kozaric A, Vranic S, Kurtovic S, Hasic A, Kozaric M, Granov N, Ceric T. Lack of Access to Targeted Cancer Treatment Modalities in the Developing World in the Era of Precision Medicine: Real-Life Lessons From Bosnia. J Glob Oncol 2017; 4:1-5. [PMID: 30241174 PMCID: PMC6180810 DOI: 10.1200/jgo.2016.008698] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Affiliation(s)
- Amina Kurtovic-Kozaric
- Amina Kurtovic-Kozaric, Semir Vranic, Sabira Kurtovic, Mirza Kozaric, Nermir Granov, and Timur Ceric, Clinical Center of the University of Sarajevo; Amina Kurtovic-Kozaric, Semir Vranic, Nermir Granov, Timur Ceric and Azra Hasic, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
| | - Semir Vranic
- Amina Kurtovic-Kozaric, Semir Vranic, Sabira Kurtovic, Mirza Kozaric, Nermir Granov, and Timur Ceric, Clinical Center of the University of Sarajevo; Amina Kurtovic-Kozaric, Semir Vranic, Nermir Granov, Timur Ceric and Azra Hasic, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
| | - Sabira Kurtovic
- Amina Kurtovic-Kozaric, Semir Vranic, Sabira Kurtovic, Mirza Kozaric, Nermir Granov, and Timur Ceric, Clinical Center of the University of Sarajevo; Amina Kurtovic-Kozaric, Semir Vranic, Nermir Granov, Timur Ceric and Azra Hasic, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
| | - Azra Hasic
- Amina Kurtovic-Kozaric, Semir Vranic, Sabira Kurtovic, Mirza Kozaric, Nermir Granov, and Timur Ceric, Clinical Center of the University of Sarajevo; Amina Kurtovic-Kozaric, Semir Vranic, Nermir Granov, Timur Ceric and Azra Hasic, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
| | - Mirza Kozaric
- Amina Kurtovic-Kozaric, Semir Vranic, Sabira Kurtovic, Mirza Kozaric, Nermir Granov, and Timur Ceric, Clinical Center of the University of Sarajevo; Amina Kurtovic-Kozaric, Semir Vranic, Nermir Granov, Timur Ceric and Azra Hasic, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
| | - Nermir Granov
- Amina Kurtovic-Kozaric, Semir Vranic, Sabira Kurtovic, Mirza Kozaric, Nermir Granov, and Timur Ceric, Clinical Center of the University of Sarajevo; Amina Kurtovic-Kozaric, Semir Vranic, Nermir Granov, Timur Ceric and Azra Hasic, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
| | - Timur Ceric
- Amina Kurtovic-Kozaric, Semir Vranic, Sabira Kurtovic, Mirza Kozaric, Nermir Granov, and Timur Ceric, Clinical Center of the University of Sarajevo; Amina Kurtovic-Kozaric, Semir Vranic, Nermir Granov, Timur Ceric and Azra Hasic, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
| |
Collapse
|
9
|
Balasubramanian P, Chopra A, Verma D, Singh IK, Kumar A, Sharma A, Kumar R. Imatinib resistance in chronic myeloid leukemia due to a rare mutation. Leuk Lymphoma 2016; 58:1750-1752. [DOI: 10.1080/10428194.2016.1256479] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
| | - Anita Chopra
- Department of Laboratory Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences, New Delhi, India
| | - Deepak Verma
- Department of Laboratory Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences, New Delhi, India
| | - Indresh K. Singh
- Department of Laboratory Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences, New Delhi, India
| | - Akash Kumar
- Department of Medical Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences, New Delhi, India
| | - Atul Sharma
- Department of Medical Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences, New Delhi, India
| | - Rajive Kumar
- Department of Laboratory Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences, New Delhi, India
| |
Collapse
|
10
|
Patkar N, Ghodke K, Joshi S, Chaudhary S, Mascerhenas R, Dusseja S, Mahadik S, Gaware S, Tembhare P, Gujral S, Kabre S, Kadam-Amare P, Jain H, Dangi U, Bagal B, Khattry N, Sengar M, Arora B, Narula G, Banavali S, Menon H, Subramanian PG. Characteristics ofBCR-ABLkinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance. Leuk Lymphoma 2016; 57:2653-60. [DOI: 10.3109/10428194.2016.1157868] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
11
|
Kurtovic-Kozaric A, Hasic A, Radich JP, Bijedic V, Nefic H, Eminovic I, Kurtovic S, Colakovic F, Kozaric M, Vranic S, Bovan NS. The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients. Br J Haematol 2015; 172:420-7. [DOI: 10.1111/bjh.13843] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2015] [Accepted: 09/22/2015] [Indexed: 11/29/2022]
Affiliation(s)
- Amina Kurtovic-Kozaric
- Department of Pathology; University Clinical Centre Sarajevo; Sarajevo Bosnia and Herzegovina
- Department of Biology; Faculty of Natural Sciences; University of Sarajevo; Sarajevo Bosnia and Herzegovina
- Department of Genetics and Bioengineering; International Burch University; Sarajevo Bosnia and Herzegovina
| | - Azra Hasic
- Department of Biology; Faculty of Natural Sciences; University of Sarajevo; Sarajevo Bosnia and Herzegovina
| | - Jerald P. Radich
- Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle WA USA
| | - Vildan Bijedic
- Haematology Clinic; University Clinical Centre Sarajevo; Sarajevo Bosnia and Herzegovina
| | - Hilada Nefic
- Department of Biology; Faculty of Natural Sciences; University of Sarajevo; Sarajevo Bosnia and Herzegovina
| | - Izet Eminovic
- Department of Biology; Faculty of Natural Sciences; University of Sarajevo; Sarajevo Bosnia and Herzegovina
| | - Sabira Kurtovic
- Haematology Clinic; University Clinical Centre Sarajevo; Sarajevo Bosnia and Herzegovina
| | - Ferida Colakovic
- Haematology Clinic; Cantonal Hospital Zenica; Zenica Bosnia and Herzegovina
| | - Mirza Kozaric
- Centre for Mother and Child; University Clinical Centre Sarajevo; Sarajevo Bosnia and Herzegovina
- Department of Genetics and Bioengineering; International Burch University; Sarajevo Bosnia and Herzegovina
| | - Semir Vranic
- Department of Pathology; University Clinical Centre Sarajevo; Sarajevo Bosnia and Herzegovina
| | - Nada S. Bovan
- Department of Internal Medicine; Clinical Hospital Mostar; Mostar Bosnia and Herzegovina
| |
Collapse
|
12
|
Pagnano KBB, Bendit I, Boquimpani C, De Souza CA, Miranda ECM, Zalcberg I, Larripa I, Nardinelli L, Silveira RA, Fogliatto L, Spector N, Funke V, Pasquini R, Hungria V, Chiattone CS, Clementino N, Conchon M, Moiraghi EB, Lopez JL, Pavlovsky C, Pavlovsky MA, Cervera EE, Meillon LA, Simões B, Hamerschlak N, Bozzano AHM, Mayta E, Cortes J, Bengió RM. BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival. Cancer Invest 2015; 33:451-8. [PMID: 26288116 DOI: 10.3109/07357907.2015.1065499] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p = 0.07 and 47% vs. 72%, p = 0.03, respectively) and in those with the T315I mutation (p = 0.003 and p = 0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p = 0.01; PFS: 48% vs. 30% p = 0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients.
Collapse
Affiliation(s)
| | - Israel Bendit
- b 2 Laboratório de Biologia Tumoral , University of São Paulo, São Paulo , São Paulo, Brazil
| | | | | | - Eliana C M Miranda
- a 1 Hemocentro-UNICAMP , University of Campinas, Campinas , São Paulo, Brazil
| | - Ilana Zalcberg
- d 4 Instituto Nacional do Câncer, Rio de Janeiro , Rio de Janeiro, Brazil
| | - Irene Larripa
- e 5 Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina de Buenos Aires , Buenos Aires, Argentina
| | - Luciana Nardinelli
- b 2 Laboratório de Biologia Tumoral , University of São Paulo, São Paulo , São Paulo, Brazil
| | | | - Laura Fogliatto
- f 6 Hospital das Clínicas de Porto Alegre, Porto Alegre , Rio Grande do Sul, Brazil
| | - Nelson Spector
- g 7 Federal University of Rio de Janeiro , Rio de Janeiro , Rio de Janeiro, Brazil
| | - Vaneuza Funke
- h 8 Universidade Federal do Paraná , Curitiba, Paraná, Brazil
| | | | - Vania Hungria
- i 9 Santa Casa de São Paulo, São Paulo , São Paulo, Brazil
| | | | - Nelma Clementino
- j 10 Universidade Federal de Minas Gerais , Belo Horizonte , Minas Gerais, Brazil
| | - Monika Conchon
- k 11 Hospital Santa Marcelina , São Paulo, São Paulo, Brazil
| | | | | | | | | | | | | | - Belinda Simões
- q 17 University of São Paulo , Ribeirão Preto, São Paulo, Brazil
| | | | | | | | - Jorge Cortes
- u 21 MD Anderson Cancer Center , Houston, Texas, USA
| | - Raquel M Bengió
- e 5 Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina de Buenos Aires , Buenos Aires, Argentina
| | | |
Collapse
|
13
|
Xia DY, Liu L, Hao MW, Liu Q, Chen RA, Liang YM. A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia. ACTA ACUST UNITED AC 2014. [PMID: 25387678 PMCID: PMC4244677 DOI: 10.1590/1414-431x20143734] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
p15INK4B, a cyclin-dependent kinase inhibitor, has been recognized as a tumor
suppressor. Loss of or methylation of the p15INK4B gene in chronic
myeloid leukemia (CML) cells enhances myeloid progenitor formation from common
myeloid progenitors. Therefore, we examined the effects of overexpressed p15INK4B on
proliferation and apoptosis of CML cells. Overexpression of p15INK4B inhibited the
growth of K562 cells by downregulation of cyclin-dependent kinase 4 (CDK4) and cyclin
D1 expression. Overexpression of p15INK4B also induced apoptosis of K562 cells by
upregulating Bax expression and downregulating Bcl-2 expression. Overexpression of
p15INK4B together with STI571 (imatinib) or BCR-ABL1 small interfering RNA (siRNA)
also enhanced growth inhibition and apoptosis induction of K562 cells. The enhanced
effect was also mediated by reduction of cyclin D1 and CDK4 and regulation of Bax and
Bcl-2. In conclusion, our study may provide new insights into the role of p15INK4B in
CML and a potential therapeutic target for overcoming tyrosine kinase inhibitor
resistance in CML.
Collapse
Affiliation(s)
- D Y Xia
- Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China
| | - L Liu
- Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China
| | - M W Hao
- Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China
| | - Q Liu
- Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China
| | - R A Chen
- Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China
| | - Y M Liang
- Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China
| |
Collapse
|
14
|
Sweet K, Al Ali NH, Dalia SM, Komrokji RS, Crescentini RM, Tinsley S, Lancet JE, Papenhausen PR, Zhang L, Pinilla-Ibarz J. Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia. Int J Hematol 2014; 100:567-74. [DOI: 10.1007/s12185-014-1685-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Revised: 09/22/2014] [Accepted: 09/23/2014] [Indexed: 12/31/2022]
|
15
|
Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MWN, Martinelli G, Müller MC, Radich JP, Shah NP. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res 2013; 38:10-20. [PMID: 24131888 DOI: 10.1016/j.leukres.2013.09.011] [Citation(s) in RCA: 109] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2013] [Accepted: 09/12/2013] [Indexed: 12/18/2022]
Abstract
Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T315I mutant has proven particularly difficult to target. This review summarizes the prevalence, impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detection of mutations.
Collapse
Affiliation(s)
- Simona Soverini
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
| | - Susan Branford
- Department of Molecular Pathology, SA Pathology, Centre for Cancer Biology, Adelaide, Australia; School of Medicine, University of Adelaide, Adelaide, Australia; School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia
| | - Franck E Nicolini
- Hematology Department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - Moshe Talpaz
- Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
| | - Michael W N Deininger
- Division of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA
| | - Giovanni Martinelli
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - Martin C Müller
- III Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany
| | - Jerald P Radich
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Neil P Shah
- Department of Hematology/Oncology, University of California, San Francisco, CA, USA
| |
Collapse
|
16
|
Ferri C, Bianchini M, Icardi G, Belli C, Bengió R, Larripa I. Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR-ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction. Leuk Lymphoma 2012; 54:598-606. [PMID: 22870928 DOI: 10.3109/10428194.2012.718767] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BCR-ABL1 point mutations are the most common cause of resistance in patients with chronic myeloid leukemia (CML) who fail or lose response to tyrosine kinase inhibitors. We have developed a rapid method to screen BCR-ABL1 mutations by high resolution melting (HRM). We designed a strategy based on amplification refractory mutational system-quantitative polymerase chain reaction (ARMS-qPCR) to identify and quantify several clinically relevant mutations. From 856 patients with CML studied during 2 years in our laboratory, we selected 32 who showed persistent levels of BCR-ABL1 transcripts (>0.1%) in at least two consecutive studies. Using our strategy, we identified mutations in 11/32 cases (34.4%), while only two of them (6.2%) were detectable by sequencing. Furthermore, we were able to estimate the timing and dynamics of mutated clones, evaluating retrospective samples from the same patient. In cases with lack or loss of molecular response this analysis might be useful for designing early therapeutic strategies.
Collapse
Affiliation(s)
- Cristian Ferri
- Instituto de Medicina Experimental (IMEX, CONICET-ANM), Academia Nacional de Medicina, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina.
| | | | | | | | | | | |
Collapse
|